TCGA-DQ-7591-01A-11R-2081-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.410
- SPERMATOGENESIS+0.340
- G2M_CHECKPOINT+0.280
- ALLOGRAFT_REJECTION+0.110
- PANCREAS_BETA_CELLS+0.110
- MITOTIC_SPINDLE+0.020
- KRAS_SIGNALING_DN+0.000
- APICAL_SURFACE-0.080
- IL6_JAK_STAT3_SIGNALING-0.090
- BILE_ACID_METABOLISM-0.120
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.600
- UNFOLDED_PROTEIN_RESPONSE-0.470
- ANGIOGENESIS-0.460
- MYOGENESIS-0.450
- CHOLESTEROL_HOMEOSTASIS-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- APICAL_JUNCTION-0.420
- P53_PATHWAY-0.420
- APOPTOSIS-0.390
- TGF_BETA_SIGNALING-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BB-4223-01A-01R-1436-07 | — | — | 0.954 |
| 2 | SRR934810 | — | — | 0.903 |
| 3 | SRR934905 | — | — | 0.901 |
| 4 | TCGA-BB-4224-01A-01R-1436-07 | — | — | 0.900 |
| 5 | TCGA-QK-A6IF-01A-11R-A31N-07 | — | — | 0.900 |
| 6 | C3L-02616 | — | cohortMD1 | 0.895 |
| 7 | SRR934771 | — | — | 0.895 |
| 8 | BS_W311713R | medulloblastoma | — | 0.893 |
| 9 | TCGA-QK-A6V9-01A-11R-A34R-07 | — | — | 0.889 |
| 10 | BS_7FWZ518S | medulloblastoma | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.340 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.110 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |